Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapiesNicola Lawson, Craig Barker|Modern Pathology|2019Cited by 87
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaSophie Wildsmith, Ricard Mesı́a, Song Wu et al.|Clinical Cancer Research|2023Cited by 30